Compare SIDU & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | TELA |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7M | 51.2M |
| IPO Year | 2021 | 2019 |
| Metric | SIDU | TELA |
|---|---|---|
| Price | $1.02 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | ★ 3.1M | 356.4K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,623,538.00 | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | $100.00 | $15.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $0.63 | $0.86 |
| 52 Week High | $7.65 | $3.10 |
| Indicator | SIDU | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 45.98 |
| Support Level | $0.73 | $1.10 |
| Resistance Level | $1.25 | $1.21 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 61.43 | 31.58 |
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.